<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2720">
  <stage>Registered</stage>
  <submitdate>31/03/2010</submitdate>
  <approvaldate>31/03/2010</approvaldate>
  <nctid>NCT01097707</nctid>
  <trial_identification>
    <studytitle>A Study in Men With Benign Prostatic Hyperplasia</studytitle>
    <scientifictitle>A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>I1A-MC-BPAE</secondaryid>
    <secondaryid>10373</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Benign Prostatic Hyperplasia</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - LY500307
Treatment: drugs - Placebo

Experimental: 1mg LY500307 - 

Experimental: 3mg LY500307 - 

Experimental: 10mg LY500307 - 

Experimental: 25mg LY500307 - 

Placebo Comparator: Placebo - 


Treatment: drugs: LY500307
Administered orally, daily for 24 weeks

Treatment: drugs: Placebo
Administered orally, daily for 24 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline to 24 week endpoint in International Prostate Symptom Score (IPSS) total score</outcome>
      <timepoint>Baseline, 24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to 24 week endpoint in Total Prostate Volume (TPV)</outcome>
      <timepoint>Baseline, 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to 24 weeks endpoint in Peak Urinary Flow Rate (Qmax)</outcome>
      <timepoint>Baseline, 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to 24 week endpoint in International Prostate Symptom Score-Quality of Life Index (IPSS-QoL)</outcome>
      <timepoint>Baseline, 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to 24 week endpoint in International Prostate Symptom Score storage, voiding and nocturia subscores</outcome>
      <timepoint>Baseline, 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to 24 week endpoint in Prostate Specific Antigen (PSA)</outcome>
      <timepoint>Baseline, 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in fasting total testosterone</outcome>
      <timepoint>Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks, 28-32 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Lipid Profile</outcome>
      <timepoint>Baseline, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks, 28-32 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Present at screening with a history of BPH for &gt;6 months.

          -  Have an IPSS greater than or equal to 13 at screening.

          -  Have a Total Prostate Volume by Transrectal ultrasound greater than or equal to 30 mL
             at screening.

          -  Show signs of bladder outlet obstruction as defined by a peak urinary flow rate (Qmax)
             greater than or equal to 4 and less than or equal to 15 mL/sec (from a prevoid total
             bladder volume [assessed by ultrasound] of greater than or equal to 150 to less than
             or equal to 550 ml and a minimum voided volume of 125 ml) at screening.

          -  Have a PSA greater than or equal to 1.4 and less than or equal to 10 ng/mL at
             screening.

          -  Demonstrate a Post Void Residual less than or equal to 300 mL by ultrasound at
             screening.

          -  Have not received the following treatments within the specified time period:

               1. Finasteride or dutasteride for at least 6 months prior to screening.

               2. Any alpha-adrenergic antagonists for at least 4 weeks prior to screening.

               3. Any other non-experimental BPH therapy (including an herbal preparation) for at
                  least 4 weeks prior to screening.

               4. Any other experimental or off-label BPH therapy such as injectable therapies with
                  a protracted effect for at least 6 months prior to screening.

               5. Any overactive bladder treatment for at least 4 weeks prior to screening.

               6. Any Erectile Dysfunction treatment which may include oral phosphodiesterase type
                  5 inhibitors or devices for at least 4 weeks prior to screening.

          -  Have a morning fasting Total Testosterone concentration greater than or equal to 300
             ng/dL at screening.

          -  If hyperlipidemic, based on history, be on stable statin treatment as determined by
             the investigator for at least 2 months prior to screening.</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Have completed or withdrawn from this study or have completed or withdrawn from any
             other study investigating LY500307.

          -  Have any history of BPH-related invasive procedures (for example, Transurethral
             Resection of the Prostate, open prostatectomy, and minimally invasive procedures that
             include thermal-based therapies, transurethral microwave treatment, transurethral
             needle ablation, and stents).

          -  Have active cardiovascular disease as evidenced by the following:

               1. Recent Myocardial infarction, unstable angina, stroke or Transient ischemic
                  attach within 6 months of screening.

               2. Recent coronary intervention that includes coronary artery bypass surgery,
                  percutaneous coronary artery intervention, or stent placement within 6 months of
                  screening.

               3. Recent history of positive stress tests without any written documentation of
                  effective intervention within 6 months of screening.

               4. Evidence of heart disease categorized as greater than or equal to Class III
                  functional classification of NYHA within 6 months of screening.

          -  Have known or suspected history of prostate cancer, breast cancer, or other clinically
             significant neoplastic disease (other than squamous cell or basal cell carcinoma of
             skin).

          -  Have a history of deep venous thrombosis or pulmonary embolism disease.

          -  Have moderate to severe renal insufficiency.

          -  Have a hemoglobin A1c (HbA1c) greater than 9.0%.

          -  Are on testosterone replacement therapy, or drugs that influence the
             hypothalamus-pituitary-gonadal axis.

          -  Are on pharmacological treatment other than statins for hyperlipidemia.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>414</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC,WA</recruitmentstate>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Adelaide</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Bentleigh East</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Mentone</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Nedlands</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3165 - Bentleigh East</postcode>
    <postcode>3194 - Mentone</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alaska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Montana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Garches</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nimes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Orleans</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Bergzabern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Holzminden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Marburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Oranienburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Reutlingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Heraklion</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Larissa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Patras</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Cefala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Rostov-On-Don</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic
      Hyperplasia (BPH)</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01097707</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>